Alan Armstrong bought Genmab AS (NASDAQ: GMAB)
Alan Armstrong (R-OK), a U.S. Senator, has disclosed 1 trade in Genmab AS (GMAB) since 2026, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Alan Armstrong bought $1,001 - $15,000 of Genmab AS (NASDAQ: GMAB) on March 30, 2026. Since that trade, GMAB is up +10.41% against the S&P 500 up +15.43%, an outperformance of -5.01%.
Data updated
Alan Armstrong's GMAB trades vs the price
GMAB is up +10.41% since Alan Armstrong bought on March 30, 2026, versus +15.43% for the S&P 500.
Performance since this trade
All Alan Armstrong GMAB trades
Alan Armstrong & GMAB trading FAQ
Is it legal for Alan Armstrong to trade Genmab AS (GMAB) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Genmab AS (GMAB), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Alan Armstrong buy GMAB?
Alan Armstrong disclosed a purchase of $1,001 - $15,000 of Genmab AS (GMAB) on March 30, 2026, according to public STOCK Act filings.
How has GMAB performed since Alan Armstrong's trade?
Since Alan Armstrong bought GMAB on March 30, 2026, the stock is up +10.41%, versus +15.43% for the S&P 500 over the same period, an outperformance of -5.01%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional GMAB trades?
Quantellect tracks every disclosed congressional trade in Genmab AS (GMAB) on the Genmab AS congressional trading page, which aggregates filings across all members of Congress.
Alan Armstrong's GMAB tradesAll congressional filings for Genmab ASAlan Armstrong's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.